Moderna (MRNA) Reports Wide Q3 Loss on $3.1B Charge, as Revenues Beat

Go back to Moderna (MRNA) Reports Wide Q3 Loss on $3.1B Charge, as Revenues Beat

Moderna (MRNA) downside has played out, HSBC raises rating

November 3, 2023 9:49 AM EDT

Moderna (NASDAQ: MRNA) was raised to Hold from Reduce at HSBC on Friday, with the firm raising the price target for the stock to $89 from $69 per share.

The investment bank's analyst, Yifeng Liu, said that the downside they saw for the company has... More